Last update 24 Mar 2025

Bezetabart debotansine

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Anti-CD74 antibody drug conjugates (Sutro Biopharma, Inc.), BN301, SP-7219
+ [4]
Action
inhibitors
Mechanism
CD74 inhibitors(HLA-DR antigens-associated invariant chain inhibitors), Tubulin inhibitors
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 2
China
25 Nov 2022
Follicular LymphomaPhase 2
China
25 Nov 2022
Mantle-Cell LymphomaPhase 2
China
25 Nov 2022
Hematologic NeoplasmsPhase 1
China
07 Sep 2022
Multiple MyelomaPhase 1
United States
22 Feb 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
18
rblinbujzb(majoizqywx) = chills, fatigue, nausea, anemia, headache, pyrexia, infusion reaction, decreased appetite, and abdominal pain occurring in ≥ 20% of patients. dkxlhhlwud (ocfrykyznp )
Positive
05 Nov 2020
Not Applicable
-
oydszfyctl(axvqmkwdxy) = Myelosuppression was observed at the highest dose, with no off-target toxicity vmqsyrdjgd (pideplslsa )
Positive
07 Jun 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free